PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7795141

European regulatory issues.

J Betts
View original source ↗Export metadata ↓

Abstract

Current EU regulations do not cover all aspects of the manufacture and control of blood products. Recent legislation coming into force on 1 January 1995 has established the European Medicines Evaluation Agency and introduced revised systems for approving pharmaceutical products, including blood products. There remains a need for comprehensive harmonized legislation covering plasma collection and screening, virus validation studies, and batch release.

Explore related subjects

Biological FactorsBloodBlood BanksBlood ProteinsEuropean UnionGuidelines as TopicHumansSafetySocial Control, FormalVirus DiseasesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Betts. 1994. European regulatory issues.. https://doi.org/10.1097/00001721-199412004-00016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

C-type natriuretic peptide: a new endothelium-derived hyperpolarizing factor?

Vascular relaxation mediated by endothelium-derived hyperpolarizing factor (EDHF) is important for resistance artery function and is underpinned by hyperpolarization of the smooth muscle cells of the blood vessel wall. Debate surrounds the identity of EDHF and its mechanism of action, with the consensus being that there is no universal EDHF. Regional differences in vascular function reflect the complex mechanisms of EDHF. Two primary mechanistic pathways are implicated: (i) myoendothelial gap junctions mediating the spread of endothelial cell hyperpolarization or small signaling molecules (or both) to the smooth muscle; and (ii) diffusible mediators released from the endothelium, including K+ and epoxyeicosatrienoic acids. Here, we discuss the evidence for and against C-type natriuretic peptide (CNP), the latest candidate for a diffusible mediator.

Biological Factors↗